结外NK/T细胞淋巴瘤患者生存结局:国际T细胞项目前瞻性队列研究
该研究基于国际T细胞项目前瞻性队列,纳入166例新诊断结外NK/T细胞淋巴瘤成人患者,中位随访44个月,鼻型患者5年总生存率为54%,鼻外型为34%,提示近十年常规临床实践中生存改善。
要点
- 鼻型ENKTL患者5年OS为54%,鼻外型为34%。
- 166例ENKTL占1553例合格注册病例的11%。
- 生存改善可能归因于ENKTL特异性治疗方案的增加使用。
核心结论
- 过去十年常规临床实践中ENKTL患者生存有临床显著改善,可能归因于特异性治疗方案的增加使用。
研究设计与样本
- 国际T细胞项目的前瞻性队列子研究,纳入13国74中心连续诊断的成人(>18岁)新诊断未治疗成熟T细胞或NK淋巴瘤患者。
主要发现
- 中位随访44个月(IQR 20-61),鼻型ENKTL患者(n=98)5年总生存率为54%(95% CI 44-63)。
- 鼻外型ENKTL患者(n=68)5年总生存率为34%(95% CI 27-46)。
临床怎么用
- 应关注鼻外型ENKTL患者预后更差,5年OS仅34%。
- 常规临床实践中可考虑采用ENKTL特异性治疗方案以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information available from international cohorts. The effects of treatment advances on routine clinical practice across continental territories has not been clear. We aimed to improve understanding of the clinical characteristics and outcomes of patients with ENKTL. METHODS: We did a substudy of patients with ENKTL from the T-cell Project, a global prospective cohort study. The T-cell Project registered consecutively diagnosed adults (>18 years) with newly diagnosed, untreated mature T-cell or NK lymphomas (WHO 2001 or 2008 classifications) from 74 centres in 13 countries (in Asia, Europe, North America, and South America). In total, 1695 patients with mature T-cell or NK lymphomas were enrolled between Oct 12, 2006 and Feb 28, 2018 in the T-cell Project. The first patient with ENKTL was enrolled on Feb 15, 2007, and the last on May 26, 2017. Data on baseline characteristics, first-line treatment, treatment response, and survival outcomes were recorded in a central database (locked March 30, 2019). The primary outcome was 5-year overall survival. The T-cell Project is registered on ClinicalTrials.gov, NCT01142674. FINDINGS: 166 patients were diagnosed with ENKTL, comprising 11% of 1553 eligible registered cases and distributed across 40 participating centres in four continents. At a median follow-up of 44 months (IQR 20-61), overall survival at 5 years was 54% (95% CI 44-63) in patients with nasal disease (n=98) and 34% (27-46) in patients with extranasal disease (n=68). INTERPRETATION: To our knowledge, this study presents the largest international cohort of patients with ENKTL. We describe a clinically significant improvement in the survival of patients with ENKTL treated in routine clinical practice over the past decade, likely to be attributable to the increasing use of treatment protocols specific for ENKTL. FUNDING: The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the National Cancer Institute at the National Institutes of Health.
引用
- Fox CP, Civallero M, Ko YH, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020. PMID: 32105608. doi:10.1016/S2352-3026(19)30283-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。